Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II research study is evaluating a combination of drugs called paclitaxel and
ruxolitinib as a possible treatment for inflammatory breast cancer. Ruxolitinib is a newly
discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that
may be important in cancer, including breast cancer. Blocking this pathway may stop cancer
cells from growing. Ruxolitinib has been approved by the FDA for patients with bone marrow
disease, and this is the first study using this drug in combination with paclitaxel for
breast cancer. Paclitaxel (also called Taxol) is an FDA drug approved for breast cancer
patients. Paclitaxel works by blocking the small microtubules inside cancer cells and
preventing cell growth. Information from laboratory experiments suggests that ruxolitinib
might also have effects on breast cancer.These studies have shown that ruxolitinib may make
paclitaxel more effective.